

## **NCI Guidelines for ARRA Research and Research Infrastructure “Grand Opportunities”**

[RFA-OD-09-004](#) - Recovery Act Limited Competition for NIH Grants: Research and Research Infrastructure “Grand Opportunities” (RC2)

The purpose of the Research and Research Infrastructure Grand Opportunities program is to support high impact ideas that lend themselves to short-term, non-renewable funding, and may lay the foundation for new fields of investigation. The program will support large-scale research projects that accelerate critical breakthroughs, early and applied research on cutting-edge technologies, and new approaches to improve the synergy and interactions among multi and interdisciplinary research teams.

This initiative is one of several being offered by ICs to fulfill the goals of the American Recovery and Reinvestment Act (ARRA) to help stimulate the economy through support of biomedical and behavioral research. Additional information the Recovery Act and related NIH opportunities is available through the [Office of Extramural Research](#).

### **Areas of Scientific Priority:**

For this initiative, examples of scientific interest areas include, but are not limited to the following:

- [Nanotechnology](#)
- [Proteomics](#)
- Stem Cells
- Early Phase Clinical Trials
- Transcriptional and Translational Regulation
- Comparative Oncology Research

### **Funding Priorities:**

Overall, the IC expects to devote \$10,000,000 to the Grand Opportunity program.

### **Key Dates:**

Release/Posted Date: March 20, 2009

Opening Date: April 27, 2009 (Earliest date an application may be submitted to Grants.gov)

Letters of Intent Receipt Date(s): April 27, 2009

**NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).**

Application Due Date(s): May 27, 2009

AIDS Application Due Date(s): Not applicable

Peer Review Date(s): June/July 2009

Council Review Date(s): August 2009

Earliest Anticipated Start Date(s): September 30, 2009

Additional Information To Be Available Date (Activation Date): Not Applicable

Expiration Date: May 28, 2009

### **Contact Information:**

#### NCI Contacts (By Topic)

- Nanotechnology – Piotr Grodzinski, PhD, 301-496-1550, [grodzinp@mail.nih.gov](mailto:grodzinp@mail.nih.gov)
- Proteomics – Henry Rodriguez, PhD, 301-496-1550, [rodriguezr@mail.nih.gov](mailto:rodriguezr@mail.nih.gov)
- Stem Cells – Allan Mufson, PhD, 301-496-7815, [mufsonr@mail.nih.gov](mailto:mufsonr@mail.nih.gov)
- Early Phase Clinical Trials – William Timmer, PhD, 301-594-9796, [timmerw@mail.nih.gov](mailto:timmerw@mail.nih.gov)
- Transcriptional and Translational Regulation – Judy Mietz, PhD, 301-496-9326, [mietzj@mail.nih.gov](mailto:mietzj@mail.nih.gov)
- Comparative Oncology Research – Suresh Mohla, PhD, 301 435-1878, [mohlas@mail.nih.gov](mailto:mohlas@mail.nih.gov)

SRO Contact(s): David E. Maslow, PhD, 301-496-2330, [dm65y@nih.gov](mailto:dm65y@nih.gov)

Grants Management Contact: Crystal Wolfrey, 301-496-8634, [wolfreyc@mail.nih.gov](mailto:wolfreyc@mail.nih.gov)